Literature DB >> 23609618

Progress in gene therapy for neurological disorders.

Michele Simonato1, Jean Bennett, Nicholas M Boulis, Maria G Castro, David J Fink, William F Goins, Steven J Gray, Pedro R Lowenstein, Luk H Vandenberghe, Thomas J Wilson, John H Wolfe, Joseph C Glorioso.   

Abstract

Diseases of the nervous system have devastating effects and are widely distributed among the population, being especially prevalent in the elderly. These diseases are often caused by inherited genetic mutations that result in abnormal nervous system development, neurodegeneration, or impaired neuronal function. Other causes of neurological diseases include genetic and epigenetic changes induced by environmental insults, injury, disease-related events or inflammatory processes. Standard medical and surgical practice has not proved effective in curing or treating these diseases, and appropriate pharmaceuticals do not exist or are insufficient to slow disease progression. Gene therapy is emerging as a powerful approach with potential to treat and even cure some of the most common diseases of the nervous system. Gene therapy for neurological diseases has been made possible through progress in understanding the underlying disease mechanisms, particularly those involving sensory neurons, and also by improvement of gene vector design, therapeutic gene selection, and methods of delivery. Progress in the field has renewed our optimism for gene therapy as a treatment modality that can be used by neurologists, ophthalmologists and neurosurgeons. In this Review, we describe the promising gene therapy strategies that have the potential to treat patients with neurological diseases and discuss prospects for future development of gene therapy.

Entities:  

Mesh:

Year:  2013        PMID: 23609618      PMCID: PMC3908892          DOI: 10.1038/nrneurol.2013.56

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  150 in total

1.  Antisense oligonucleotide therapy for neurodegenerative disease.

Authors:  Richard A Smith; Timothy M Miller; Koji Yamanaka; Brett P Monia; Thomas P Condon; Gene Hung; Christian S Lobsiger; Chris M Ward; Melissa McAlonis-Downes; Hongbing Wei; Ed V Wancewicz; C Frank Bennett; Don W Cleveland
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

2.  Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

Authors:  Jeffrey H Kordower; Christopher D Herzog; Biplob Dass; Roy A E Bakay; James Stansell; Mehdi Gasmi; Raymond T Bartus
Journal:  Ann Neurol       Date:  2006-12       Impact factor: 10.422

3.  Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism.

Authors:  Marina E Emborg; Maren Carbon; James E Holden; Matthew J During; Yilong Ma; Chengke Tang; Jeffrey Moirano; Helen Fitzsimons; Ben Z Roitberg; Eray Tuccar; Andrew Roberts; Michael G Kaplitt; David Eidelberg
Journal:  J Cereb Blood Flow Metab       Date:  2006-07-12       Impact factor: 6.200

Review 4.  Angels and demons: neurotrophic factors and epilepsy.

Authors:  Michele Simonato; Enrico Tongiorgi; Merab Kokaia
Journal:  Trends Pharmacol Sci       Date:  2006-10-19       Impact factor: 14.819

5.  Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.

Authors:  Krystof S Bankiewicz; John Forsayeth; Jamie L Eberling; Rosario Sanchez-Pernaute; Philip Pivirotto; John Bringas; Peter Herscovitch; Richard E Carson; William Eckelman; Bryan Reutter; Janet Cunningham
Journal:  Mol Ther       Date:  2006-07-07       Impact factor: 11.454

6.  Seizure suppression by GDNF gene therapy in animal models of epilepsy.

Authors:  Irene Kanter-Schlifke; Biljana Georgievska; Deniz Kirik; Merab Kokaia
Journal:  Mol Ther       Date:  2007-03-27       Impact factor: 11.454

7.  Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo.

Authors:  S Foti; R P Haberman; R J Samulski; T J McCown
Journal:  Gene Ther       Date:  2007-08-23       Impact factor: 5.250

8.  A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease.

Authors:  Cassia N Cearley; John H Wolfe
Journal:  J Neurosci       Date:  2007-09-12       Impact factor: 6.167

9.  Prolonged preservation of nerve function in diabetic neuropathy in mice by herpes simplex virus-mediated gene transfer.

Authors:  M Chattopadhyay; M Mata; J Goss; D Wolfe; S Huang; J C Glorioso; D J Fink
Journal:  Diabetologia       Date:  2007-05-17       Impact factor: 10.122

10.  GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS.

Authors:  Masatoshi Suzuki; Jacalyn McHugh; Craig Tork; Brandon Shelley; Sandra M Klein; Patrick Aebischer; Clive N Svendsen
Journal:  PLoS One       Date:  2007-08-01       Impact factor: 3.240

View more
  76 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

Review 2.  Gene therapy for the neurological manifestations in lysosomal storage disorders.

Authors:  Seng H Cheng
Journal:  J Lipid Res       Date:  2014-03-29       Impact factor: 5.922

Review 3.  What Is Next for Retinal Gene Therapy?

Authors:  Luk H Vandenberghe
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-15       Impact factor: 6.915

Review 4.  The value of EGFRvIII as the target for glioma vaccines.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

5.  Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.

Authors:  Nathan VanderVeen; Nicholas Raja; Elizabeth Yi; Henry Appelman; Philip Ng; Donna Palmer; Daniel Zamler; Marta Dzaman; Pedro R Lowenstein; Maria G Castro
Journal:  Hum Gene Ther Methods       Date:  2016-04-28       Impact factor: 2.396

6.  Arginine-rich polyplexes for gene delivery to neuronal cells.

Authors:  Viola B Morris; Vinod Labhasetwar
Journal:  Biomaterials       Date:  2015-05-22       Impact factor: 12.479

Review 7.  Adeno-associated virus-based Alzheimer's disease mouse models and potential new therapeutic avenues.

Authors:  Lars M Ittner; Matthias Klugmann; Yazi D Ke
Journal:  Br J Pharmacol       Date:  2019-04-23       Impact factor: 8.739

Review 8.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

9.  Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain.

Authors:  Giridhar Murlidharan; Andrew Crowther; Rebecca A Reardon; Juan Song; Aravind Asokan
Journal:  JCI Insight       Date:  2016-09-08

Review 10.  Pathological pain and the neuroimmune interface.

Authors:  Peter M Grace; Mark R Hutchinson; Steven F Maier; Linda R Watkins
Journal:  Nat Rev Immunol       Date:  2014-02-28       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.